More on BIVI
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.61 |
|
|||
| Open | $1.64 | ||||
| 52 Wk High | $0.40 | ||||
| 52 Wk Low | $0.17 | ||||
| Day High | $1.76 | ||||
| Day Low | $1.62 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 411,521 | ||||
- New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
- Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
- BioVie to host investor webinar on Phase 2 Long COVID trial data
- Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results
- BioVie reports Phase 2 Long COVID drug trial results in subgroups
- BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
- BioVie to discuss Phase 2 Long Covid trial results in conference call
- BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
- Form 8-K BIOVIE INC. For: Sep 11
- Form 424B5 BIOVIE INC.
Entities mentioned with BIVI
- FDA | View Related Stories »
- Dividend | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- ThinkEquity | View Related Stories »
- S1 | View Related Stories »
- Show More...
